The rationale of targeting neutrophils with dapsone during glioblastoma treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 756-761

  Kast, Richard E ^a   Scheuerle, Angelika ^b   Wirtz, Christian R ^b   Karpel Massler, Georg ^b   Halatsch, Marc Eric ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Angiogenesis; Chemotaxis; Chemotherapy; Dapsone; Glioblastoma; Neutrophils; Temozolomide; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CIMETIDINE; DAPSONE; INTERLEUKIN 8; VASCULOTROPIN;

ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BULLOUS PEMPHIGOID; CANCER GROWTH; CHEMORADIOTHERAPY; DERMATITIS HERPETIFORMIS; DRUG EXCRETION; DRUG METABOLISM; GLIOBLASTOMA; HUMAN; LEPROSY; LEUKOCYTE ACTIVATION; MAXIMUM PLASMA CONCENTRATION; METHEMOGLOBINEMIA; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PROGNOSIS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 80053544587     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378805     Document Type: Review

References (81)

1. Ohgaki, H.; Kleihues, P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol., 2005, 64, 479-489.
2. Stupp, R.; Hegi, M.E.; Gilbert, M.R.; Chakravarti, A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin. Oncol., 2007, 25, 4127-4136.
3. Homma, T.; Fukushima, T.; Vaccarella, S.; Yonekawa, Y.; Di Patre, P.L.; Franceschi, S.; Ohgaki, H. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol., 2006, 65, 846-854.
4. Desbaillets, I.; Diserens, A.C.; Tribolet, N.; Hamou, M.F.; Van Meir, E.G. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med., 1997, 186, 1201-1212.
5. Fossati, G.; Ricevuti, G.; Edwards, S.W.; Walker, C.; Dalton, A.; Rossi, M.L. Neutrophil infiltration into human gliomas. Acta Neuropathol., 1999, 98, 349-354.
6. Iwatsuki, K.; Kumara, E.; Yoshimine, T.; Nakagawa, H.; Sato, M.; Hayakawa, T. Elastase expression by infiltrating neutrophils in gliomas. Neurol. Res., 2000, 22, 465-468.
7. Atai, N.A.; Bansal, M.; Lo, C.; Bosman, J.; Tigchelaar, W.; Bosch, K.S.; Jonker, A.; De Witt Hamer, P.C.; Troost, D.; McCulloch, C.A.; Everts, V.; Van Noorden, C.J.; Sodek, J. Osteopontin is upregulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology, 2011, 132, 39-48.
8. Hong, X.; Nelson, K.K.; deCarvalho, A.C.; Kalkanis, S.N. Heparanase expression of glioma in human and animal models. J. Neurosurg., 2010, 113, 261-269.
9. Collins, P.D.; Connolly, D.T.; Williams, T.J. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br. J. Pharmacol., 1993, 109, 195-199.
10. Taichman, N.S.; Young, S.; Cruchley, A.T.; Taylor, P.; Paleolog, E. Human neutrophils secrete vascular endothelial growth factor. J. Leukoc. Biol., 1997, 62, 397-400.
11. Caye-Thomasen, P.; Larsen, K.; Tingsgaard, P.; Tos, M. Immunohistochemical demonstration and semi-quantitation of vascular endothelial growth factor in recurrent versus non-recurrent nasal polyps. Acta Otolaryngol., 2004, 124, 706-711.
12. Mueller, M.D.; Lebovic, D.I.; Garrett, E.; Taylor, R.N. Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil. Steril., 2000, 74, 107-112.
13. Na, Y.J.; Yang, S.H.; Baek, D.W.; Lee, D.H.; Kim, K.H.; Choi, Y.M.; Oh, S.T.; Hong, Y.S.; Kwak, J.Y.; Lee, K.S. Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. Hum. Reprod., 2006, 21, 1846-1855.
14. Ohki, Y.; Heissig, B.; Sato, Y.; Akiyama, H.; Zhu, Z.; Hicklin, D.J.; Shimada, K.; Ogawa, H.; Daida, H.; Hattori, K.; Ohsaka, A. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J., 2005, 19, 2005-2007.
15. Tee, M.K.; Vigne, J.L.; Taylor, R.N. All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation. Endocrinology, 2006, 147, 1264-1270.
16. Kusumanto, Y.H.; Dam, W.A.; Hospers, G.A.; Meijer, C.; Mulder, N.H. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis, 2003, 6, 283-287.
17. Ancelin, M.; Chollet-Martin, S.; Herve, M.A.; Legrand, C.; El Benna, J.; Perrot-Applanat, M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab. Invest., 2004, 84, 502-512.
18. Skondra, D.; Noda, K.; Almulki, L.; Tayyari, F.; Frimmel, S.; Nakazawa, T.; Kim, I.K.; Zandi, S.; Thomas, K.L.; Miller, J.W.; Gragoudas, E.S.; Hafezi-Moghadam, A. Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown. Invest. Ophthalmol. Vis. Sci., 2008, 49, 726-731.
19. Cullen, V.C.; Mackarel, A.J.; Hislip, S.J.; O'Connor, C.M.; Keenan, A.K. Investigation of vascular endothelial growth factor effects on pulmonary endothelial monolayer permeability and neutrophil transmigration. Gen. Pharmacol., 2000, 35, 149-157.
20. Gaudry, M.; Bregerie, O.; Andrieu, V.; El Benna, J.; Pocidalo, M.A.; Hakim, J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood, 1997, 90, 4153-4161.
21. Heissig, B.; Nishida, C.; Tashiro, Y.; Sato, Y.; Ishihara, M.; Ohki, M.; Gritli, I.; Rosenkvist, J.; Hattori, K. Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration. Histol. Histopathol., 2010, 25, 765-770.
22. McCourt, M.; Wang, J.H.; Sookhai, S.; Redmond, H.P. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch. Surg., 1999, 134, 1325-1331.
23. Morozumi, T.; Kubota, T.; Sugita, N.; Ohsawa, Y.; Yamazaki, K.; Yoshie, H. Elevated mRNA expression for supervillin and vascular endothelial growth factor in human neutrophils stimulated with lipopolysaccharide from Porphyromonas gingivalis. J. Periodontal. Res., 2001, 36, 160-168.
24. Neagoe, P.E.; Brkovic, A.; Hajjar, F.; Sirois, M.G. Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors, 2009, 27, 335-344.
25. Schruefer, R.; Lutze, N.; Schymeinsky, J.; Walzog, B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H1186-1192.
26. Svendsen, M.N.; Lykke, J.; Werther, K.; Bisgaard, T.; Christensen, I.J.; Nielsen, H.J. Bacterial antigen induced release of soluble vascular endothelial growth factor (VEGF) and VEGFR1 before and after surgery. Scand. J. Clin. Lab. Invest., 2005, 65, 237-247.
27. van Der Flier, M.; Coenjaerts, F.; Kimpen, J.L.; Hoepelman, A.M.; Geelen, S.P. Streptococcus pneumoniae induces secretion of vascular endothelial growth factor by human neutrophils. Infect. Immun., 2000, 68, 4792-4794.
28. Webb, N.J.; Myers, C.R.; Watson, C.J.; Bottomley, M.J.; Brenchley, P.E. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine, 1998, 10, 254-257.
29. Kasama, T.; Shiozawa, F.; Kobayashi, K.; Yajima, N.; Hanyuda, M.; Takeuchi, H.T.; Mori, Y.; Negishi, M.; Ide, H.; Adachi, M. Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. Arthritis Rheum., 2001, 44, 2512-2524.
30. Chodobski, A.; Chung, I.; Kozniewska, E.; Ivanenko, T.; Chang, W.; Harrington, J.F.; Duncan, J.A.; Szmydynger-Chodobska, J. Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury. Neuroscience, 2003, 122, 853-867.
31. Hohenstein, A.; Erber, R.; Schilling, L.; Weigel, R. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. J. Neurotrauma, 2005, 22, 518-528.
32. Lee, T.H.; Avraham, H.; Lee, S.H.; Avraham, S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J. Biol. Chem., 2002, 277, 10445-10451.
33. Rodriguez, P.C.; Ernstoff, M.S.; Hernandez, C.; Atkins, M.; Zabaleta, J.; Sierra, R.; Ochoa, A.C. Arginase I-producing myeloidderived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res., 2009, 69, 1553-1560.
34. Jablonska, E.; Piotrowski, L.; Jablonski, J.; Grabowska, Z. VEGF in the culture of PMN and the serum in oral cavity cancer patients. Oral Oncol., 2002, 38, 605-609.
35. Jablonska, E.; Puzewska, W.; Grabowska, Z.; Jablonski, J.; Talarek, L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine, 2005, 30, 93-99.
36. Werther, K.; Bulow, S.; Hesselfeldt, P.; Jespersen, N.F.; Svendsen, M.N.; Nielsen, H.J. VEGF concentrations in tumour arteries and veins from patients with rectal cancer. APMIS, 2002, 110, 646-650.
37. Houghton, A.M. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle, 2010, 9, 1732-1737.
38. Tazzyman, S.; Lewis, C.E.; Murdoch, C. Neutrophils: key mediators of tumour angiogenesis. Int. J. Exp. Pathol., 2009, 90, 222-231.
39. Shimada, H.; Takiguchi, N.; Kainuma, O.; Soda, H.; Ikeda, A.; Cho, A.; Miyazaki, A.; Gunji, H.; Yamamoto, H.; Nagata, M. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer, 2010, 13, 170-176.
40. Aliustaoglu, M.; Bilici, A.; Seker, M.; Dane, F.; Gocun, M.; Konya, V.; Ustaalioglu, B.B.; Gumus, M. The association of pretreatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology, 2010, 57, 640-645.
41. Bhatti, I.; Peacock, O.; Lloyd, G.; Larvin, M.; Hall, R.I. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am. J. Surg., 2010, 200, 197-203.
42. Liu, H.; Liu, G.; Bao, Q.; Sun, W.; Bao, H.; Bi, L.; Wen, W.; Liu, Y.; Wang, Z.; Yin, X.; Bai, Y.; Hu, X. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J. Gastrointest. Cancer, 2010, 41, 116-120.
43. Gomez, D.; Farid, S.; Malik, H.Z.; Young, A.L.; Toogood, G.J.; Lodge, J.P.; Prasad, K.R. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J. Surg., 2008, 32, 1757-1762.
44. Halazun, K.J.; Hardy, M.A.; Rana, A.A.; Woodland, D.C.; Luyten, E.J.; Mahadev, S.; Witkowski, P.; Siegel, A.B.; Brown, R.S., Jr.; Emond, J.C. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann. Surg., 2009, 250, 141-151.
45. Sarraf, K.M.; Belcher, E.; Raevsky, E.; Nicholson, A.G.; Goldstraw, P.; Lim, E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 2009, 137, 425-428.
46. Teramukai, S.; Kitano, T.; Kishida, Y.; Kawahara, M.; Kubota, K.; Komuta, K.; Minato, K.; Mio, T.; Fujita, Y.; Yonei, T.; Nakano, K.; Tsuboi, M.; Shibata, K.; Furuse, K.; Fukushima, M. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur. J. Cancer, 2009, 45, 1950-1958.
47. Winter, M.C.; Potter, V.A.; Woll, P.J. Raised serum urea predicts for early death in small cell lung cancer. Clin Oncol (R Coll Radiol), 2008, 20, 745-750.
48. Ohno, Y.; Nakashima, J.; Ohori, M.; Hatano, T.; Tachibana, M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J. Urol., 2010, 184, 873-878.
49. Kitayama, J.; Yasuda, K.; Kawai, K.; Sunami, E.; Nagawa, H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat. Oncol., 2010, 5, 47.
50. Jensen, H.K.; Donskov, F.; Marcussen, N.; Nordsmark, M.; Lundbeck, F.; von der Maase, H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol., 2009, 27, 4709-4717.
51. Bellocq, A.; Antoine, M.; Flahault, A.; Philippe, C.; Crestani, B.; Bernaudin, J.F.; Mayaud, C.; Milleron, B.; Baud, L.; Cadranel, J. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am. J. Pathol., 1998, 152, 83-92.
52. Onishi, M.; Ichikawa, T.; Kurozumi, K.; Date, I. Angiogenesis and invasion in glioma. Brain Tumor Pathol., 2011, 28, 13-24.
53. Utsuki, S.; Oka, H.; Suzuki, S.; Shimizu, S.; Tanizaki, Y.; Kondo, K.; Tanaka, S.; Kawano, N.; Fujii, K. Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol., 2006, 23, 29-34.
54. Shojaei, F.; Ferrara, N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res., 2008, 68, 5501-5504.
55. Yao, X.H.; Ping, Y.F.; Chen, J.H.; Chen, D.L.; Xu, C.P.; Zheng, J.; Wang, J.M.; Bian, X.W. Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR. J. Neurooncol., 2008, 86, 47-53.
56. Coleman, M.D. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br. J. Dermatol., 1993, 129, 507-513.
57. Zhu, Y.I.; Stiller, M.J. Dapsone and sulfones in dermatology: overview and update. J. Am. Acad. Dermatol., 2001, 45, 420-434.
58. Rhodes, L.E.; Tingle, M.D.; Park, B.K.; Chu, P.; Verbov, J.L.; Friedmann, P.S. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol, 1995, 132, 257-262.
59. Zuidema, J.; Hilbers-Modderman, E.S.; Merkus, F.W. Clinical pharmacokinetics of dapsone. Clin. Pharmacokinet., 1986, 11, 299-315.
60. Gatti, G.; Hossein, J.; Malena, M.; Cruciani, M.; Bassetti, M. Penetration of dapsone into cerebrospinal fluid of patients with AIDS. J. Antimicrob. Chemother., 1997, 40, 113-115.
61. Rich, J.D.; Mirochnick, M. Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagn. Microbiol. Infect. Dis., 1996, 24, 77-79.
62. Semple, B.D.; Kossmann, T.; Morganti-Kossmann, M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb Blood Flow Metab., 2010, 30, 459-473.
63. Waugh, D.J.; Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res., 2008, 14, 6735-6741.
64. Atkinson, G.P.; Nozell, S.E.; Harrison, D.K.; Stonecypher, M.S.; Chen, D.; Benveniste, E.N. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene, 2009, 28, 3735-3745.
65. Brat, D.J.; Bellail, A.C.; Van Meir, E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol., 2005, 7, 122-133.
66. Charalambous, C.; Chen, T.C.; Hofman, F.M. Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg. Focus, 2006, 20, E22.
67. de la Iglesia, N.; Konopka, G.; Lim, K.L.; Nutt, C.L.; Bromberg, J.F.; Frank, D.A.; Mischel, P.S.; Louis, D.N.; Bonni, A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J. Neurosci., 2008, 28, 5870-5878.
68. Desbaillets, I.; Diserens, A.C.; de Tribolet, N.; Hamou, M.F.; Van Meir, E.G. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene, 1999, 18, 1447-1456.
69. Gabellini, C.; Castellini, L.; Trisciuoglio, D.; Kracht, M.; Zupi, G.; Del Bufalo, D. Involvement of nuclear factor-kappa B in bcl-xLinduced interleukin 8 expression in glioblastoma. J. Neurochem., 2008, 107, 871-882.
70. Magnus, N.; Garnier, D.; Rak, J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood, 2010, 116, 815-818.
71. Samaras, V.; Piperi, C.; Levidou, G.; Zisakis, A.; Kavantzas, N.; Themistocleous, M.S.; Boviatsis, E.I.; Barbatis, C.; Lea, R.W.; Kalofoutis, A.; Korkolopoulou, P. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum. Immunol., 2009, 70, 391-397.
72. Sun, S.; Wang, Q.; Giang, A.; Cheng, C.; Soo, C.; Wang, C.Y.; Liau, L.M.; Chiu, R. Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-kappaB. J. Neurooncol., 2011, 101, 1-14.
73. Xie, T.X.; Xia, Z.; Zhang, N.; Gong, W.; Huang, S. Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncol. Rep., 2010, 23, 725-732.
74. Kasperkiewicz, M.; Zillikens, D. The pathophysiology of bullous pemphigoid. Clin. Rev. Allergy Immunol., 2007, 33, 67-77.
75. Schmidt, E.; Reimer, S.; Kruse, N.; Brocker, E.B.; Zillikens, D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin. Exp. Immunol., 2001, 124, 157-162.
76. Shimanovich, I.; Mihai, S.; Oostingh, G.J.; Ilenchuk, T.T.; Brocker, E.B.; Opdenakker, G.; Zillikens, D.; Sitaru, C. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol, 2004, 204, 519-527.
77. Booth, S.A.; Moody, C.E.; Dahl, M.V.; Herron, M.J.; Nelson, R.D. Dapsone suppresses integrin-mediated neutrophil adherence function. J. Invest. Dermatol., 1992, 98, 135-140.
78. Grabbe, J.; Haas, N.; Moller, A.; Henz, B.M. Erythema elevatum diutinum - evidence for disease-dependent leucocyte alterations and response to dapsone. Br. J. Dermatol., 2000, 143, 415-420.
79. Modschiedler, K.; Weller, M.; Worl, P.; von den Driesch, P. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch. Dermatol. Res., 2000, 292, 32-36.
80. Suda, T.; Suzuki, Y.; Matsui, T.; Inoue, T.; Niide, O.; Yoshimaru, T.; Suzuki, H.; Ra, C.; Ochiai, T. Dapsone suppresses human neutrophil superoxide production and elastase release in a calciumdependent manner. Br. J. Dermatol., 2005, 152, 887-895.
81. Debol, S.M.; Herron, M.J.; Nelson, R.D. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J. Leukoc. Biol., 1997, 62, 827-836.